Normocalcemic Primary Hyperparathyroidism: A Comparison with the Hypercalcemic Form in a Tertiary Referral Population

Abstract

Normocalcemic primary hyperparathyroidism (NPHPT) is a formally recognized variant of primary hyperparathyroidism (PHPT), characterized by normal total and ionized serum calcium concentrations and elevated parathyroid hormone (PTH) levels, in the absence of secondary causes for hyperparathyroidism. NPHPT has been studied previously, but data are limited and confounded. We aimed to compare the clinical and biochemical data of normocalcemic and hypercalcemic subjects in a hospital-based population.

We retrospectively analysed the medical records of 131 subjects diagnosed with PHPT at the university hospital Brussels (UZ Brussel) between January 1st 2007 and December 31st 2016, including 25 normocalcemic and 106 hypercalcemic subjects.

The mean values of age, BMI, sex, serum 25-OH vitamin D levels and urinary phosphate excretion were comparable between both groups. Subjects diagnosed with NPHPT had significantly lower plasma PTH levels, lower urinary calcium excretion and lower serum creatinine levels compared to the hypercalcemic subjects with PHPT. Corresponding eGFR values were higher in the normocalcemic group. Normocalcemic subjects (NPHPT) presented with a high prevalence of nephrolithiasis (36%), fragility fractures (12%) and osteoporosis (25%). Clinical manifestations and BMD measurements revealed no statistically significant differences between both groups.

Our data show a relative prevalence of 19% NPHPT in PHPT. NPHPT may present the earliest form of PHPT with an extension in time, but is not an indolent disease state. Normocalcemic subjects should be managed as hypercalcemic subjects with PHPT. Further research regarding the pathophysiology and natural course of NPHPT is required.

Key words

normocalcemic - primary hyperparathyroidism - tertiary referral population

• References

• 1 John T, Potts J, Jüppner H. Disorder of the Parathyroid Gland and Calcium Homeostasis. In: Kapser DL, Fauci AS, Hauser SL, Longo DL, Jameson JL, Loscalzo J. (eds.) Harrison's Principles of Internal medicine. 19th Edition New York: McGraw-Hill; 2015: 2466-2488
• 2 Marx SJ, Lourenco Jr DM. Familial hyperparathyroidism - Disorders of growth and secretion in hormone-secretory tissue. Horm Metab Res 2017; 49: 805-815
• 3 Silverberg SJ, Bilezikian JP. Evaluation and management of primary hyperparathyroidism. J Clin Endocrinol Metab 1996; 81: 2036-2040
• 4 Bilezikian JP, Brandi ML, Eastell R, Silverberg SJ, Udelsman R, Marcocci C, Potts Jr JT. Guidelines for the management of asymptomatic primary hyperparathyroidism: Summary statement from the Fourth International Workshop. J Clin Endocrinol Metab 2014; 99: 3561-3569
• 5 Storvall S, Ryhanen EM, Heiskanen I, Sintonen H, Roine RP, Schalin-Jantti C. Surgery significantly improves neurocognition, sleep, and blood pressure in primary hyperparathyroidism: A 3-year prospective follow-up study. Horm Metab Res 2017; 49: 772-777
• 6 . Silverberg SJ, Clarke BL, Peacock M, Bandeira F, Boutroy S, Cusano NE, Dempster D, Lewiecki EM, Liu JM, Minisola S, Rejnmark L, Silva BC, Walker MD, Bilezikian JP. Current issues in the presentation of asymptomatic primary hyperparathyroidism: Proceedings of the Fourth International Workshop. J Clin Endocrinol Metab 2014; 99: 3580-3594
• 7 Eastell R, Arnold A, Brandi ML, Brown EM, D'Amour P, Hanley DA, Rao DS, Rubin MR, Goltzman D, Silverberg SJ, Marx SJ, Peacock M, Mosekilde L, Bouillon R, Lewiecki EM. Diagnosis of asymptomatic primary hyperparathyroidism: proceedings of the third international workshop. J Clin Endocrinol Metab 2009; 94: 340-350
• 8 Pawlowska M, Cusano NE. An overview of normocalcemic primary hyperparathyroidism. Curr Opin Endocrinol Diabetes Obes 2015; 22: 413-421
• 9 Rao DS, Wilson RJ, Kleerekoper M, Parfitt AM. Lack of biochemical progression or continuation of accelerated bone loss in mild asymptomatic primary hyperparathyroidism: evidence for biphasic disease course. J Clin Endocrinol Metab 1988; 67: 1294-1298
• 10 Silverberg SJ, Bilezikian JP. “Incipient” primary hyperparathyroidism: A "forme fruste" of an old disease. J Clin Endocrinol Metab 2003; 88: 5348-5352
• 11 Maruani G, Hertig A, Paillard M, Houillier P. Normocalcemic primary hyperparathyroidism: evidence for a generalized target-tissue resistance to parathyroid hormone. J Clin Endocrinol Metab 2003; 88: 4641-4648
• 12 Diaz-Soto G, Romero E, Castrillon JL, Jauregui OI, de Luis Roman D. Clinical expression of calcium sensing receptor polymorphism (a986s) in normocalcemic and asymptomatic hyperparathyroidism. Horm Metab Res 2016; 48: 163-168
• 13 Diaz-Soto G, Romero E, Perez-Castrillon JL, Jauregui OI. de Luis Roman D. Parathyroid hormone polymorphism rs6254 is associated with the development and severity of osteoporosis in asymptomatic but not normocalcemic hyperthyroidism. Horm Metab Res 2016; 48: 828-833
• 14 Lowe H, McMahon DJ, Rubin MR, Bilezikian JP, Silverberg SJ. Normocalcemic primary hyperparathyroidism: Further characterization of a new clinical phenotype. J Clin Endocrinol Metab 2007; 92: 3001-3005
• 15 Tordjman KM, Greenman Y, Osher E, Shenkerman G, Stern N. Characterization of normocalcemic primary hyperparathyroidism. Am J Med 2004; 117: 861-863
• 16 Marques TF, Vasconcelos R, Diniz E, Rego D, Griz L, Bandeira F. Normocalcemic primary hyperparathyroidism in clinical practice: An indolent condition or a silent threat?. Arq Bras Endocrinol Metabol 2011; 55: 314-317
• 17 Amaral LM, Queiroz DC, Marques TF, Mendes M, Bandeira F. Normocalcemic versus hypercalcemic primary hyperparathyroidism: More stone than bone? J Osteoporos 2012; 128352:
• 18 Cusano NE, Silverberg SJ, Bilezikian JP. Normocalcemic primary hyperparathyroidism. J Clin Densitom 2013; 16: 33-39
• 19 Eastell R, Brandi ML, Costa AG, D'Amour P, Shoback DM, Thakker RV. Diagnosis of asymptomatic primary hyperparathyroidism: proceedings of the Fourth International Workshop. J Clin Endocrinol Metab 2014; 99: 3570-3579
• 20 Bringhurst RR, Krane SM, Kronenberg HM. Bone and mineral metabolism in health and disease. In: Kasper DL, Fauci AS, Hausser SL, Longo DL, Jameson JL, Loscalzo J. (eds.). Harrison's principles of internal medicine. 19th Edition New York: McGraw-Hill; 2015: 2454-2466
• 21 Lundgren E, Rastad J, Thrufjell E, Akerstrom G, Ljunghall S. Population-based screening for primary hyperparathyroidism with serum calcium and parathyroid hormone values in menopausal women. Surgery 1997; 121: 287-294
• 22 Garcia-Martin A, Reyes-Garcia R, Munoz-Torres M. Normocalcemic primary hyperparathyroidism: One-year follow-up in one hundred postmenopausal women. Endocrine 2012; 42: 764-766